CN1234073A - 环状变更的促红细胞生成素受体激动剂 - Google Patents

环状变更的促红细胞生成素受体激动剂 Download PDF

Info

Publication number
CN1234073A
CN1234073A CN97198973A CN97198973A CN1234073A CN 1234073 A CN1234073 A CN 1234073A CN 97198973 A CN97198973 A CN 97198973A CN 97198973 A CN97198973 A CN 97198973A CN 1234073 A CN1234073 A CN 1234073A
Authority
CN
China
Prior art keywords
seq
leu
ala
glu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN97198973A
Other languages
English (en)
Chinese (zh)
Inventor
C·A·麦惠特
Y·Q·冯
N·萨默斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of CN1234073A publication Critical patent/CN1234073A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN97198973A 1996-10-25 1997-10-23 环状变更的促红细胞生成素受体激动剂 Pending CN1234073A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3404496P 1996-10-25 1996-10-25
US60/034,044 1996-10-25

Publications (1)

Publication Number Publication Date
CN1234073A true CN1234073A (zh) 1999-11-03

Family

ID=21873960

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97198973A Pending CN1234073A (zh) 1996-10-25 1997-10-23 环状变更的促红细胞生成素受体激动剂

Country Status (13)

Country Link
US (1) US20060172932A1 (https=)
EP (1) EP0939816A1 (https=)
JP (1) JP2001503266A (https=)
KR (1) KR20000052807A (https=)
CN (1) CN1234073A (https=)
AU (1) AU721196B2 (https=)
BR (1) BR9712675A (https=)
CA (1) CA2268001A1 (https=)
CZ (1) CZ130199A3 (https=)
NO (1) NO991906L (https=)
NZ (1) NZ334546A (https=)
PL (1) PL189756B1 (https=)
WO (1) WO1998018926A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110144010A (zh) * 2018-02-14 2019-08-20 上海洛启生物医药技术有限公司 阻断型pd-l1驼源单域抗体及其用途

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
CN100383238C (zh) 2003-05-09 2008-04-23 克鲁塞尔荷兰公司 E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法
JP2008527980A (ja) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド 分子およびそのキメラ分子
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20190006086A (ko) 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US20080260746A1 (en) * 2005-11-24 2008-10-23 Laboratoires Serono Sa Erythropoietin Polypeptides and Uses Thereof
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2111229B1 (en) 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
ES2756725T3 (es) 2007-02-09 2020-04-27 Acceleron Pharma Inc Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
SMT202300222T1 (it) 2008-08-14 2023-09-06 Acceleron Pharma Inc Trappole di gdf
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
BRPI1010587A2 (pt) 2009-06-08 2019-04-09 Acceleron Pharma Inc. métodos para aumentar adipócitos termogênicos
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
RS61391B1 (sr) 2012-06-08 2021-02-26 Alkermes Pharma Ireland Ltd Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
CA2069746A1 (en) * 1990-09-28 1992-03-29 Jonathan I. Rosen Hybrid growth factors
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110144010A (zh) * 2018-02-14 2019-08-20 上海洛启生物医药技术有限公司 阻断型pd-l1驼源单域抗体及其用途
WO2019158113A1 (zh) * 2018-02-14 2019-08-22 上海洛启生物医药技术有限公司 阻断型pd-l1驼源单域抗体及其用途
US11912770B2 (en) 2018-02-14 2024-02-27 Shanghai Novamab Biopharmaceuticals Co., Ltd. Blocking type PD-L1 single-domain camel antibody and application thereof

Also Published As

Publication number Publication date
PL332960A1 (en) 1999-10-25
NO991906D0 (no) 1999-04-21
PL189756B1 (pl) 2005-09-30
AU5081098A (en) 1998-05-22
NZ334546A (en) 2000-12-22
JP2001503266A (ja) 2001-03-13
NO991906L (no) 1999-04-21
US20060172932A1 (en) 2006-08-03
CZ130199A3 (cs) 1999-07-14
AU721196B2 (en) 2000-06-29
BR9712675A (pt) 1999-10-19
KR20000052807A (ko) 2000-08-25
EP0939816A1 (en) 1999-09-08
WO1998018926A1 (en) 1998-05-07
CA2268001A1 (en) 1998-05-07

Similar Documents

Publication Publication Date Title
CN1234073A (zh) 环状变更的促红细胞生成素受体激动剂
CN1146440C (zh) 血管内皮生长因子-b
AU734594B2 (en) Circularly permuted polypeptides as novel stem cell factor receptor agonists
CN1283659C (zh) 截短的神经胶质细胞系来源的神经营养因子
CN1823087A (zh) 结合红细胞生成素受体的新肽
CN1602201A (zh) 具有血小板生成活性的肽和相关的化合物
CN1823088A (zh) 结合红细胞生成素受体的新肽
CN1227604A (zh) 多种变异的il－3造血生成融合蛋白
CN1157408C (zh) 以糖蛋白激素四成员家族的单链形式存在的糖蛋白激素活性的促效剂或拮抗剂
CN1219967A (zh) 神经胶质细胞系源性的神经营养因子受体
AU733964B2 (en) Novel flt-3 receptor agonists
CN1150458A (zh) 用于刺激造血的通式为gm-csf-l-epo或epo-l-gm-csf的杂合分子
CN1340102A (zh) 高肝素结合力的多肽变异体
CN1124348C (zh) 多功能性造血受体激动剂
CN1197876C (zh) 含有分子内伴侣样序列的嵌合蛋白及其在胰岛素生产中的应用
CN1169158A (zh) 具有增强稳定性和生物活性的酸性成纤维细胞增长因子类似物
CN1190437A (zh) 骨刺激因子
CN1653177A (zh) 1型胎盘生长因子的突变蛋白及其制备方法和应用
HK1023145A (en) Circularly permuted erythropoietin receptor agonists
CN1131309C (zh) 白细胞介素－6突变蛋白
CN1202129C (zh) Gdnf突变体及其治疗应用
MXPA99003874A (es) Agonistas del receptor de eritropoyetina circularmente permutados
CN1242049A (zh) 多功能嵌合造血受体激动剂
HK1115143A (en) Peptides and related compounds having thrombopoietic activity
HK1025353A (en) Multi-functional chimeric hematopoietic receptor agonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1023145

Country of ref document: HK